ResMed (RMD) stock price, news and key stats

Price

Last close as of Sep 16, 2026. Delayed data; not a live quote.

Previous close

$229.44

Open

$228.19

Day range

$224.26 – $229.32

Volume

1.0M

About ResMed

Latest RMD news

• Seattle firm Frazier Healthcare Partners closes $490 million acquisition of software company
  Private Equity · Sep 2, 2026

  Frazier Healthcare Partners, a Seattle-based private equity firm specializing in the healthcare sector, has successfully closed its acquisition of MatrixCare, a cloud-based electronic health record (EHR) provider, for $490 million in cash. This acquisition marks Frazier's second significant purchase in recent months, expanding its healthcare-focused portfolio to a total of 17 companies. The deal, which was finalized after ResMed, the seller, announced its intention to divest the software business, reflects a growing trend of consolidation in the healthcare technology space. The acquisition of MatrixCare is poised to enhance Frazier's strategic positioning within the rapidly evolving healthcare landscape, particularly as demand for digital health solutions continues to rise. The integration of MatrixCare's EHR capabilities is expected to bolster Frazier's existing portfolio, providing enhanced services to healthcare providers and improving patient care through advanced technology. Market analysts suggest that this move could signal increased investment in healthcare IT, as firms seek to capitalize on the ongoing digital transformation in the industry. As the healthcare sector increasingly embraces technology-driven solutions, Frazier's acquisition could also have broader implications for the market. Investors may view this transaction as a signal of confidence in the growth potential of healthcare software, potentially leading to increased valuations for similar companies. Furthermore, the successful integration of MatrixCare into Frazier's portfolio may set a precedent for future acquisitions, as private equity firms look to leverage technology to enhance operational efficiencies and patient outcomes in the healthcare sector.

• Oxygen Conservers Market Outlook Signals Expansion To $3.45 Billion Through 2030
  Market Outlook · Aug 21, 2026

  The oxygen conservers market is projected to expand significantly, reaching an estimated value of $3.45 billion by 2030, according to a recent analysis by Market Outlook. This growth is driven by an increasing prevalence of respiratory diseases, an aging population, and rising awareness about the benefits of oxygen therapy. The demand for portable oxygen solutions, which enhance mobility and quality of life for patients, is particularly contributing to this upward trend. Market dynamics indicate that technological advancements in oxygen conservation devices are also playing a crucial role in this expansion. Innovations such as improved battery life, compact designs, and enhanced user interfaces are making these devices more accessible and appealing to consumers. As healthcare systems globally continue to prioritize patient-centered care, the adoption of oxygen conservers is expected to rise, further boosting market growth. From an investment perspective, companies involved in the production and distribution of oxygen conservers may see increased interest from investors looking to capitalize on the growing healthcare sector. Additionally, the expansion of telehealth services and home healthcare solutions could create new opportunities for market players, as more patients seek convenient and effective management of their respiratory conditions. Overall, the oxygen conservers market is poised for robust growth, reflecting broader trends in healthcare and patient management.

Index membership

• S&P 500 · Health Care

Related Health Care stocks

• AAgilent Technologies
• ABBVAbbVie
• ABTAbbott Laboratories
• ALGNAlign Technology
• AMGNAmgen
• BAXBaxter International
• BDXBecton Dickinson
• BIIBBiogen